SlideShare ist ein Scribd-Unternehmen logo
1 von 23
Joris Veltman (onderzoeker)
Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
Het probleem; Ineffectieve medicijnen!
1953
Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59  TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1  TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ?        OF   	Fout in aantal chromosomen?
Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
Genoomdiagnostiek in 2015  DNA ? Genoomsequentie < 1 uur < 500 euro
Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en  Bioinformatica expertise! Totale genoomsequentie 1 individu
ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
NRC 13 feb 2010
Personal genomics en impact op geneeskunde
Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen  verschillen
Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
THANK YOU !
NEXT

Weitere ähnliche Inhalte

Was ist angesagt?

Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
spa718
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
Analiese Wenger
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 Zincfinger
Ryla Best
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assays
nanog
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
Simon Silvan
 

Was ist angesagt? (19)

Qpcr
QpcrQpcr
Qpcr
 
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
 
Present and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesPresent and future of oncolytic virus therapies
Present and future of oncolytic virus therapies
 
7 immunology-csbrp
7 immunology-csbrp7 immunology-csbrp
7 immunology-csbrp
 
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
 
PNAS 1992 FBH.PDF
PNAS 1992 FBH.PDFPNAS 1992 FBH.PDF
PNAS 1992 FBH.PDF
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
 
2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides
 
Seminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling systemSeminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling system
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 Zincfinger
 
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assays
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
 
HPV vaccine (UID198612)
HPV vaccine (UID198612)HPV vaccine (UID198612)
HPV vaccine (UID198612)
 
ProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene OlingerProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene Olinger
 
NK Immunodeficiencies
NK ImmunodeficienciesNK Immunodeficiencies
NK Immunodeficiencies
 
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsSources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
 

Ähnlich wie Joris Veltman

2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
Simon Gemble
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013
Elsa von Licy
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013
Elsa von Licy
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
European School of Oncology
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Thermo Fisher Scientific
 

Ähnlich wie Joris Veltman (20)

04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel
 
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
 
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
 
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013
 
Paneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosPaneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidos
 
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
 
Apoptosis
ApoptosisApoptosis
Apoptosis
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013
 
Diaz-Arrastia, Ramon
Diaz-Arrastia, RamonDiaz-Arrastia, Ramon
Diaz-Arrastia, Ramon
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
 
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
 
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDTuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MD
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptx
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
 
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
 

Mehr von UMC St Radboud (20)

Astrid Hartendorf
Astrid HartendorfAstrid Hartendorf
Astrid Hartendorf
 
Annet van Betuw
Annet van BetuwAnnet van Betuw
Annet van Betuw
 
Floortje Agema
Floortje AgemaFloortje Agema
Floortje Agema
 
Arjan Broers
Arjan BroersArjan Broers
Arjan Broers
 
Yvonne Engels en Jeroen Fokke
Yvonne Engels en Jeroen FokkeYvonne Engels en Jeroen Fokke
Yvonne Engels en Jeroen Fokke
 
Marjolein Roes
Marjolein RoesMarjolein Roes
Marjolein Roes
 
Erich Taubert
Erich TaubertErich Taubert
Erich Taubert
 
Geert Klein Breteler
Geert Klein BretelerGeert Klein Breteler
Geert Klein Breteler
 
Erik Jansen
Erik JansenErik Jansen
Erik Jansen
 
Irene Muller
Irene MullerIrene Muller
Irene Muller
 
Joia Stoutjesdijk
Joia StoutjesdijkJoia Stoutjesdijk
Joia Stoutjesdijk
 
Sietske van der Veldt
Sietske van der VeldtSietske van der Veldt
Sietske van der Veldt
 
Ellen van Bodegom
Ellen van BodegomEllen van Bodegom
Ellen van Bodegom
 
Saskia Timmer
Saskia TimmerSaskia Timmer
Saskia Timmer
 
Rob Speekenbrink
Rob SpeekenbrinkRob Speekenbrink
Rob Speekenbrink
 
Jaco van Duivenbode
Jaco van DuivenbodeJaco van Duivenbode
Jaco van Duivenbode
 
Salmaan Sana
Salmaan SanaSalmaan Sana
Salmaan Sana
 
Bart Timmers
Bart TimmersBart Timmers
Bart Timmers
 
Martijn vd Eijk
Martijn vd EijkMartijn vd Eijk
Martijn vd Eijk
 
Michiel Sedelaar
Michiel SedelaarMichiel Sedelaar
Michiel Sedelaar
 

Kürzlich hochgeladen

Artificial Intelligence: Facts and Myths
Artificial Intelligence: Facts and MythsArtificial Intelligence: Facts and Myths
Artificial Intelligence: Facts and Myths
Joaquim Jorge
 
EIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptx
EIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptxEIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptx
EIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptx
Earley Information Science
 

Kürzlich hochgeladen (20)

Scaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organizationScaling API-first – The story of a global engineering organization
Scaling API-first – The story of a global engineering organization
 
Raspberry Pi 5: Challenges and Solutions in Bringing up an OpenGL/Vulkan Driv...
Raspberry Pi 5: Challenges and Solutions in Bringing up an OpenGL/Vulkan Driv...Raspberry Pi 5: Challenges and Solutions in Bringing up an OpenGL/Vulkan Driv...
Raspberry Pi 5: Challenges and Solutions in Bringing up an OpenGL/Vulkan Driv...
 
Data Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt RobisonData Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt Robison
 
Artificial Intelligence: Facts and Myths
Artificial Intelligence: Facts and MythsArtificial Intelligence: Facts and Myths
Artificial Intelligence: Facts and Myths
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
 
How to convert PDF to text with Nanonets
How to convert PDF to text with NanonetsHow to convert PDF to text with Nanonets
How to convert PDF to text with Nanonets
 
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps ScriptAutomating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Script
 
Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024
 
EIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptx
EIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptxEIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptx
EIS-Webinar-Prompt-Knowledge-Eng-2024-04-08.pptx
 
[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf
 
Tech Trends Report 2024 Future Today Institute.pdf
Tech Trends Report 2024 Future Today Institute.pdfTech Trends Report 2024 Future Today Institute.pdf
Tech Trends Report 2024 Future Today Institute.pdf
 
The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024
 
GenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day PresentationGenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day Presentation
 
Driving Behavioral Change for Information Management through Data-Driven Gree...
Driving Behavioral Change for Information Management through Data-Driven Gree...Driving Behavioral Change for Information Management through Data-Driven Gree...
Driving Behavioral Change for Information Management through Data-Driven Gree...
 
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
 
Finology Group – Insurtech Innovation Award 2024
Finology Group – Insurtech Innovation Award 2024Finology Group – Insurtech Innovation Award 2024
Finology Group – Insurtech Innovation Award 2024
 
A Domino Admins Adventures (Engage 2024)
A Domino Admins Adventures (Engage 2024)A Domino Admins Adventures (Engage 2024)
A Domino Admins Adventures (Engage 2024)
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
 

Joris Veltman

  • 2. Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
  • 5. Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
  • 6.
  • 7. NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59 TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1 TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
  • 8. Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ? OF Fout in aantal chromosomen?
  • 9. Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
  • 10. Genoomdiagnostiek in 2015 DNA ? Genoomsequentie < 1 uur < 500 euro
  • 11. Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
  • 12. Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en Bioinformatica expertise! Totale genoomsequentie 1 individu
  • 13. ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
  • 14. NRC 13 feb 2010
  • 15. Personal genomics en impact op geneeskunde
  • 16. Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen verschillen
  • 17.
  • 18. Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
  • 19.
  • 20. Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
  • 21. Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
  • 23. NEXT